PF-Atlas › Clinical Trials › NCT06237335
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
RCT2100 · Phase 2
Registry ID
NCT06237335
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
RCT2100
Sponsor
ReCode Therapeutics
Start
2024-02-01
Enrollment
128
Locations
23
About this trial
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06237335 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.